AbbVie Reports Q3 Earnings Beat and Raises Full-Year Guidance
AbbVie (ABBV) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted Non-GAAP earnings per share of $3.82, surpassing estimates by $0.05, while total revenue reached $17.4 billion, a 10.3% increase year-over-year that beat projections by $50 million. The performance was driven largely by the company's immunology portfolio, which generated $9.165 billion in global net revenues, representing a 16.3% increase on a reported basis. Following these strong results, AbbVie has raised its full-year financial guidance, signaling confidence in its continued growth trajectory.
Tickers: $ABBV